GlassScriptPhysician profile
David Rex Curfman
NPI 1619263720
$3,418.30
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $1,036 · 2021: $760 · 2022: $482.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,008.97 | 2019-2021 | |
| Abbvie INC. | $344.16 | 2019-2021 | |
| Amgen INC. | $204.60 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $175.41 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $149.38 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $135.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $135.54 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $107.88 | 2019-2022 | |
| Greenwich Biosciences, INC. | $97.04 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $93.46 | 2020-2022 | |
| Ucb, INC. | $85.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $75.89 | 2022 | |
| Lilly USA, LLC | $68.32 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $66.09 | 2019-2022 | |
| Biogen, INC. | $59.88 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $53.87 | 2019 | |
| Acadia Pharmaceuticals INC | $48.01 | 2022 | |
| Acorda Therapeutics, INC | $45.92 | 2019 | |
| Genzyme Corporation | $43.95 | 2019 | |
| Grifols USA, LLC | $35.79 | 2019 | |
| Sunovion Pharmaceuticals INC. | $35.75 | 2019-2020 | |
| Avion Pharmaceuticals | $32.55 | 2022 | |
| Zyla Life Sciences, INC. | $32.53 | 2019 | |
| Neurocrine Biosciences, INC. | $31.33 | 2019 | |
| Genentech USA, INC. | $28.61 | 2019 | |
| Emd Serono, INC. | $28.36 | 2019 | |
| Eisai INC. | $24.68 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.10 | 2019 | |
| Sk Life Science, INC. | $16.75 | 2022 | |
| Novo Nordisk INC | $13.56 | 2019 | |
| Assertio Therapeutics, INC. | $13.51 | 2019 | |
| Promius Pharma LLC | $12.85 | 2019 | |
| Amarin Pharma, INC. | $12.29 | 2019 | |
| W. L. Gore & Associates, INC. | $12.15 | 2020 | |
| Kyowa Kirin, INC. | $11.97 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Curfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.